Effects of trimetazidine on interleukin-2 and interleukin-8 concentrations in patients with coronary artery disease.

about

Effects of trimetazidine on interleukin-2 and interleukin-8 concentrations in patients with coronary artery disease.

Item

http://www.wikidata.org/entity/Q51122090

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Effects of trimetazidine on in ...... with coronary artery disease.

@en

Effects of trimetazidine on in ...... with coronary artery disease.

@nl

type

Item

label

Effects of trimetazidine on in ...... with coronary artery disease.

@en

Effects of trimetazidine on in ...... with coronary artery disease.

@nl

prefLabel

Effects of trimetazidine on in ...... with coronary artery disease.

@en

Effects of trimetazidine on in ...... with coronary artery disease.

@nl

P1476

Effects of trimetazidine on in ...... s with coronary artery disease

@en

P2093

Aleksander Danikiewicz

http://www.w3.org/2001/XMLSchema#string

Ilona Korzonek-Szlacheta

http://www.w3.org/2001/XMLSchema#string

Janusz Szkodziński

http://www.w3.org/2001/XMLSchema#string

Mariusz Gąsior

http://www.w3.org/2001/XMLSchema#string

P2860

Pathogenesis of acute coronary syndromes

Trimetazidine protects against smoking-induced left ventricular remodeling via attenuating oxidative stress, apoptosis, and inflammation

Trimetazidine does not modify blood levels and immunosuppressant effects of cyclosporine A in renal allograft recipients.

Inflammatory biomarkers in coronary artery disease.

Interleukin-8 as an independent predictor of long-term clinical outcome in patients with coronary artery disease.

Treatment of stable angina with low dose diltiazem in combination with the metabolic agent trimetazidine.

Serum tumour necrosis factor-alpha, interleukin-2 and interleukin-10 activation in stable angina and acute coronary syndromes.

The role of inflammation markers in triggering acute coronary events.

The anti-anginal drug trimetazidine reduces neutrophil-mediated cardiac reperfusion injury.

Suppression of angioplasty-related inflammation by pre-procedural treatment with trimetazidine.

P304

759-762

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1139/CJPP-2016-0424

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Bartosz Hudzik

Barbara Zubelewicz-Szkodzińska

P577

2017-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28238270

http://www.w3.org/2001/XMLSchema#string